Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
Disclosure of transactions in own shares between 18/06/2019 and 21/06/2019
- 25 June 2019 - 0 mins read
Related Press Releases
![Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
10 June 2024
12 mins read
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
![Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
07 June 2024
6 mins read
Ipsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform
![Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
06 June 2024
5 mins read
Ipsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer
![Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
05 June 2024
7 mins read
Ipsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis
![Ipsen appoints Keira Driansky as EVP, President of North America Ipsen appoints Keira Driansky as EVP, President of North America](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
02 May 2024
5 mins read
Ipsen appoints Keira Driansky as EVP, President of North America
![Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
24 April 2024
7 mins read
Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance
![Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
22 April 2024
5 mins read
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases
![Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors](https://www.ipsen.com/websites/ipsen_com_v2/wp-content/uploads/2023/05/28120505/PR_final.jpeg)
02 April 2024
7 mins read
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors
![Ipsen S.A. publishes its 2023 Consolidated Financial Statements Ipsen S.A. publishes its 2023 Consolidated Financial Statements](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
15 February 2024
1 mins read
Ipsen S.A. publishes its 2023 Consolidated Financial Statements
![Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA](https://www.ipsen.com/wp-content/themes/ipsen-main/dist/images/PR-final.jpg)
13 February 2024
14 mins read